Health Care [ 11/12 ] | Biotechnology [ 48/74 ]
NYSE | Common Stock
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.
The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.
In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections.
Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services.
The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -2.32 Decreased by -118.87% | -0.94 Decreased by -146.81% |
| May 1, 24 | 0.59 Increased by +118.61% | -0.86 Increased by +168.60% |
| Mar 6, 24 | -0.77 Decreased by -148.39% | -0.19 Decreased by -305.26% |
| Nov 8, 23 | -0.54 Increased by +57.48% | -0.22 Decreased by -145.45% |
| Aug 8, 23 | -1.06 Decreased by -23.26% | -0.49 Decreased by -116.33% |
| May 9, 23 | -3.17 Decreased by -1.86 K% | -1.24 Decreased by -155.65% |
| Feb 27, 23 | -0.31 Decreased by -106.89% | 0.04 Decreased by -875.00% |
| Nov 8, 22 | -1.27 Decreased by -252.78% | -0.06 Decreased by -2.02 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 269.50 M Decreased by -0.37% | 114.80 M Increased by +143.17% | Increased by +42.60% Increased by +143.33% |
| Jun 30, 24 | 254.70 M Decreased by -24.62% | -283.10 M Decreased by -8.34% | Decreased by -111.15% Decreased by -43.73% |
| Mar 31, 24 | 300.40 M Increased by +81.95% | 9.00 M Increased by +104.92% | Increased by +3.00% Increased by +102.70% |
| Dec 31, 23 | 276.60 M Decreased by -16.36% | -49.50 M Increased by +43.75% | Decreased by -17.90% Increased by +32.75% |
| Sep 30, 23 | 270.50 M Increased by +12.71% | -265.90 M Decreased by -251.25% | Decreased by -98.30% Decreased by -211.65% |
| Jun 30, 23 | 337.90 M Increased by +39.23% | -261.30 M Decreased by -363.30% | Decreased by -77.33% Decreased by -232.77% |
| Mar 31, 23 | 165.10 M Decreased by -46.31% | -183.00 M Decreased by -4.85 K% | Decreased by -110.84% Decreased by -9.11 K% |
| Dec 31, 22 | 330.70 M Decreased by -54.27% | -88.00 M Decreased by -146.49% | Decreased by -26.61% Decreased by -201.66% |